Yahoo Finance

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today announced the publication of preclinical data for its lead candidate, ZI-MA4-1, ...
Yahoo Finance

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial

On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026 Important step in developing scalable and accessible ‘off-the-shelf’ cell therapy for ...
Hosted on MSN

Zelluna secures MHRA approval to begin ZIMA-101 trail

Zelluna has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) approval for its clinical trial application (CTA) to start the ZIMA-101 first ...
PharmiWeb

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours Oslo, Norway, 22 April 2025 – ...
BioWorld

Zelluna’s ZI-MA4-1 gains UK CTA clearance for solid tumors

Zelluna ASA has received approvals from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) and research ethics committee for its clinical trial application (CTA) for ZI-MA4-1, ...
Finanznachrichten

Zelluna ASA: Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Strong preclinical data support planned clinical trial initiation in 2026 Oslo, Norway, 16 December 2025- Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today ...